Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Profit After Tax (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Profit After Tax for 3 consecutive years, with -$7.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Profit After Tax rose 53.18% to -$7.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$41.6 million, a 8.26% increase, with the full-year FY2024 number at -$43.3 million, down 46.79% from a year prior.
  • Profit After Tax was -$7.0 million for Q3 2025 at Mereo BioPharma, up from -$14.6 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$1.8 million in Q2 2023 to a low of -$15.0 million in Q3 2024.
  • A 3-year average of -$9.7 million and a median of -$9.1 million in 2023 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: tumbled 599.89% in 2024, then soared 53.18% in 2025.
  • Mereo BioPharma's Profit After Tax stood at -$9.1 million in 2023, then increased by 22.64% to -$7.0 million in 2024, then grew by 0.31% to -$7.0 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Profit After Tax are -$7.0 million (Q3 2025), -$14.6 million (Q2 2025), and -$12.9 million (Q1 2025).